成人特应性皮炎管理指南聚焦更新
美国皮肤病学会基于2023至2024年指南,针对新获批的局部和系统疗法,通过多学科工作组系统评价并采用GRADE方法,新增4条强烈推荐,涉及tapinarof乳膏、roflumilast乳膏、lebrikizumab和nemolizumab联合局部治疗。
要点
- 新增4条强烈推荐:tapinarof乳膏、roflumilast乳膏、lebrikizumab和nemolizumab联合局部治疗。
- 推荐基于系统评价和GRADE方法评估证据 certainty 并分级。
- 多数随机对照试验疗程短,限制长期疗效和安全性比较结论。
核心结论
- 工作组对tapinarof乳膏、roflumilast乳膏、lebrikizumab和nemolizumab联合局部治疗成人特应性皮炎作出强烈推荐。
研究设计与样本
- 多学科工作组进行系统评价,采用GRADE方法评估证据 certainty 并制定推荐。
主要发现
- 工作组制定了4条关于成人特应性皮炎管理的新推荐。
关键数值与推荐
- 强烈推荐使用tapinarof乳膏、roflumilast乳膏、lebrikizumab和nemolizumab,均需联合局部治疗。
临床怎么用
- 临床可考虑将tapinarof乳膏、roflumilast乳膏、lebrikizumab或nemolizumab联合局部治疗用于成人特应性皮炎。
局限性
- 分析基于实施时最佳证据,多数随机对照试验疗程短,限制长期疗效和安全性比较结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2023 and 2024, the American Academy of Dermatology published guidelines on the use of topical and systemic therapies for the management of atopic dermatitis (AD) in adults. Since the publication of these guidelines, several novel therapies have emerged to treat AD. OBJECTIVE: To update previous guidelines on the management of AD in adults by providing evidence-based recommendations on the use of additional Food and Drug Administration-approved topical and systemic therapies. METHODS: A multidisciplinary workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. RESULTS: The workgroup developed 4 new recommendations for the management of AD in adults. LIMITATIONS: This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of the considered therapies for AD are of short duration, limiting comparative long-term efficacy and safety conclusions. CONCLUSIONS: The workgroup developed strong recommendations for the use of tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab with concomitant topical therapy.
引用
- Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025. PMID: 40531067. doi:10.1016/j.jaad.2025.05.1386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。